NovaBridge Biosciences (NBP)
Nasdaq: NBP · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2019
Who owns NovaBridge Biosciences
As filed with the SECHolders of 5% or more
2
Everest Medicines Limited holds 16.1% of Ordinary shares, par value US$0.0001 per share, as its SCHEDULE 13D filed Aug 5, 2025 says.
Directors and officers
20
report now, of 20 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Everest Medicines Limited
SCHEDULE 13D · filed Aug 5, 2025 · Ordinary shares, par value US$0.0001 per share
Wei Fu
SCHEDULE 13D/A · filed Feb 3, 2026 · Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) · 10.4% in Aug 7, 2025
Infini Capital Management Ltd
SCHEDULE 13G · filed Feb 6, 2024 · Sponsored ADS · reported falling below 5%
What NBP reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Domestic Investors
An entity · legal entity · owns, named in the 20-F filed Apr 7, 2026
Groups Share Based Compensation
An entity · legal entity · owns, named in the 20-F filed Apr 7, 2026
Imab Hong Kong
An entity · consolidated entity · owns, named in the 20-F filed Apr 7, 2026
Management HoldCo Share Based Compensation
An entity · legal entity · owns, named in the 20-F filed Apr 7, 2026
TJBio Hangzhou Share Based Compensation
An entity · legal entity · owns, named in the 20-F filed Apr 7, 2026
TJBio Hangzhou
An investee · investee · invested in, named in the 20-F filed Apr 7, 2026
9 subsidiaries in 5 countries, from the list filed with the 20-F filed Apr 7, 2026.
Insider tradesForm 4
7sales
1purchases
0sales on a scheduled plan
3people selling
$200,000sold, in dollars
$600,000bought, in dollars
Open-market trades on Form 4 from Oct 19, 2025 to Oct 19, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 19, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 20 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Cao Sean Wuxiong | Chief Bus. Development Officer | 2 | $100,000 | 0 | 0 | $0 |
| Hagler Mark Arnold | Chief Commercial Officer | 0 | $0 | 0 | 1 | $600,000 |
| Dennis Phillip Andrew | Chief Medical Officer | 2 | $0 | 0 | 0 | $0 |
| Xu Cong Claire | EVP, Clinical Development | 3 | $0 | 0 | 0 | $0 |